IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ron Bruehlman, chief financial officer, and Mike Fedock, senior vice president, financial planning & analysis and incoming CFO, will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, at 11:00 a.m. ET.

A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

IQVIAFIN

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218561211/en/

The IQVIA Holdings Stock at the time of publication of the news with a raise of +4,60 % to 145,1EUR on Lang & Schwarz stock exchange (18. Februar 2026, 22:13 Uhr).